Results 11 to 20 of about 176,756 (350)

PARP‐1 regulates DNA repair factor availability [PDF]

open access: yesEMBO Molecular Medicine, 2018
PARP‐1 holds major functions on chromatin, DNA damage repair and transcriptional regulation, both of which are relevant in the context of cancer. Here, unbiased transcriptional profiling revealed the downstream transcriptional profile of PARP‐1 enzymatic
Matthew J Schiewer   +31 more
doaj   +3 more sources

PARP-1 couples β-catenin/TCF4 signaling to epithelial–mesenchymal transition in endometriosis [PDF]

open access: yesScientific Reports
Endometriosis exhibits epithelial–mesenchymal transition (EMT)-aligned traits that promote invasion and lesion persistence. We investigated whether poly(ADP-ribose) polymerase-1 (PARP-1) coordinates β-catenin/TCF4 activity with EMT programs and whether ...
Lu Zhang   +6 more
doaj   +2 more sources

PARP inhibitors [PDF]

open access: yesHereditary Cancer in Clinical Practice, 2015
بوليميرازات بولي (ADP - ريبوز)، التي يتم اختصارها باسم PARPs، هي مجموعة من البروتينات المألوفة التي تلعب دورًا مركزيًا في إصلاح الحمض النووي باستخدام مسار إصلاح استئصال القاعدة (BER). هناك حوالي 17 بروتينًا في هذه العائلة منها PARPs النووية الأولية هي PARP -1 و PARP -2 و PARP -3 و tankyrases 1 و 2 (PARP -5a و -5b).
Maheen Anwar   +2 more
  +6 more sources

Resveratrol derivative production by high-pressure treatment: proliferative inhibitory effects on cervical cancer cells

open access: yesFood & Nutrition Research, 2022
Background: In recent years, functional food components have attracted considerable attention. Resveratrol, a food polyphenol, has been widely studied due to its various physiological activities.
Yuki Sugahara   +7 more
doaj   +1 more source

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression [PDF]

open access: yes, 2015
To overcome cancer cells resistance to pharmacological therapy, the development of new therapeutic approaches becomes urgent. For this purpose, the use of poly(ADP-ribose) polymerase (PARP) inhibitors in combination with other cytotoxic agents could ...
CAIAFA, Paola   +11 more
core   +12 more sources

BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair

open access: yesCancer Biology & Medicine, 2022
Objective: We aimed to investigate the radiosensitizing efficacy of the poly-ADP-ribose polymerase (PARP) inhibitor, olaparib, and the Bloom syndrome protein (BLM) helicase inhibitor, ML216, in non-small cell lung cancer (NSCLC) cells.
Yangyang Kong   +13 more
doaj   +1 more source

Approaches to PET Imaging of Glioblastoma

open access: yesMolecules, 2020
Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approximately three in 100,000 adults annually. Positron emission tomography (PET) imaging provides an important non-invasive method of measuring biochemically specific targets
Lindsey R. Drake   +2 more
doaj   +1 more source

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies [PDF]

open access: yesCancers, 2020
Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)—the transfer of ADP-ribose chains onto amino acid residues—with a resultant modulation of protein function.
Yélamos López, José   +3 more
openaire   +3 more sources

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells

open access: yesDiagnostics, 2020
Objective: Despite the promise of PARP inhibitors (PARPi) for treating BRCA1/2 mutated ovarian cancer (OC), drug resistance invariably develops. We hypothesized rationale drug combinations, targeting key molecules in DNA repair pathways and the cell ...
Brian T. Burgess   +5 more
doaj   +1 more source

PARP family portraits [PDF]

open access: bronzeNature Chemical Biology, 2012
Joanne Kotz
openalex   +2 more sources

Home - About - Disclaimer - Privacy